Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis

被引：0
作者：
Thomas Wilke
Sabrina Mueller
Andreas Fuchs
Margit S. Kaltoft
Stefan Kipper
Malgorzata Cel
机构：
[1] Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM) an der Hochschule Wismar,Global Development
[2] Ingress-Health,undefined
[3] AOK PLUS,undefined
[4] Novo Nordisk A/S,undefined
[5] Novo Nordisk Pharma GmbH,undefined
[6] Novo Nordisk Region Europe,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Claims data; Cost; Effectiveness; Germany; Insulin; Liraglutide; Propensity score; Real-world; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2357 / 2370
页数：13
相关论文
共 50 条
  • [41] Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
    Ronan Roussel
    Bernard Charbonnel
    Mourad Behar
    Julie Gourmelen
    Corinne Emery
    Bruno Detournay
    Diabetes Therapy, 2016, 7 : 537 - 549
  • [42] Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China
    Salem, Ahmed
    Men, Peng
    Ramos, Mafalda
    Zhang, Yan-Jun
    Ustyugova, Anastasia
    Lamotte, Mark
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 469 - 480
  • [43] Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis
    McAdam-Marx, Carrie
    Nguyen, Hiep
    Schauerhamer, Marisa B.
    Singhal, Mukul
    Unni, Sudhir
    Ye, Xiangyang
    Cobden, David
    CLINICAL THERAPEUTICS, 2016, 38 (12) : 2642 - 2651
  • [44] Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis
    Osonoi, Takashi
    Saito, Miyoko
    Osonoi, Yusuke
    Douguchi, Satako
    Ofuchi, Kensuke
    Katoh, Makoto
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (11) : 828 - 834
  • [45] Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial
    de Wit, H. M.
    Vervoort, G. M.
    Jansen, H. J.
    de Galan, B. E.
    Tack, C. J.
    JOURNAL OF INTERNAL MEDICINE, 2016, 279 (03) : 283 - 292
  • [46] GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
    Divino, Victoria
    Boye, Kristina S.
    Lebrec, Jeremie
    DeKoven, Mitch
    Norrbacka, Kirsi
    DIABETES THERAPY, 2019, 10 (03) : 1067 - 1088
  • [47] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Ehlers, Lars Holger
    Lamotte, Mark
    Monteiro, Sofia
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    DIABETES THERAPY, 2021, 12 (05) : 1523 - 1534
  • [48] Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
    Reifsnider, Odette S.
    Pimple, Pratik
    Brand, Sarah
    Washington, Evelien Bergrath
    Shetty, Sharash
    Desai, Nihar R.
    DIABETES OBESITY & METABOLISM, 2022, 24 (04) : 652 - 661
  • [49] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
    Gao, Lan
    Zhao, Fei-Li
    Li, Shu-Chuen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 436 - 444
  • [50] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Lars Holger Ehlers
    Mark Lamotte
    Sofia Monteiro
    Susanne Sandgaard
    Pia Holmgaard
    Evan C. Frary
    Niels Ejskjaer
    Diabetes Therapy, 2021, 12 : 1523 - 1534
12345